Clinical trials
Early Breast Cancer clinical trials
Below are recruiting early breast cancer clinical trials, each written for real people, not researchers. We’re tracking 430 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07661927RecruitingPhase 2
Skipping hormone therapy for low-risk breast cancer
This trial tests whether women with very low-risk, early-stage breast cancer can safely skip hormone therapy after surgery. It is designed for women who are 60 or older and whose cancer shows no spread to lymph nodes and has favorable biology.
AngersAges 60 years+ - NCT07651345Enrolling by invitation
Helping Women Return for Overdue Breast Cancer Screening
This study tests different ways to encourage women in Singapore to return for mammograms (breast cancer screening) if they've fallen behind. You'd be randomly assigned to receive different types of reminders or support to help you schedule your screening.
SingaporeAges 50–69 - NCT07647263RecruitingPhase 2
New Drug Treatment Before Surgery for HER2-Positive Breast Cancer
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
Suzhou, JiangsuAges 18 years+ - NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT07635147Recruiting
Decision Support Tool for Advanced Breast Cancer
This study tests a digital tool designed to help patients with advanced (stage IV) breast cancer make treatment decisions. The tool may help you understand your options and feel more confident discussing them with your doctor.
Brooklyn, New YorkAges 18 years+ - NCT07630402Recruiting
Heart Imaging Study for Women With Early Breast Cancer
This study helps doctors find the best way to monitor heart health in women with HER2-positive breast cancer who are receiving a type of targeted chemotherapy. The goal is to catch any heart problems early and keep you safe during treatment.
Rochester, New YorkAges 18–79 - NCT07629206Recruiting
Freezing therapy for small, early-stage breast cancer
This study tests whether freezing a small breast tumor (cryoablation) is a safe and effective treatment option for older adults with early-stage, hormone-receptor-positive breast cancer. Instead of surgery, the goal is to destroy the tumor by freezing it in place.
Glendale, CaliforniaAges 70 years+ - NCT06693024Recruiting
Neratinib after standard therapy for HER2-positive early breast cancer
This trial is testing whether adding neratinib after standard treatment helps prevent HER2-positive early breast cancer from coming back. It is open only to patients treated at Peking University People's Hospital.
Beijing, Beijing MunicipalityAges Any age - NCT06693037Recruiting
Choosing next treatment after incomplete response in HER2+ breast cancer
This trial looks at the best next treatment for women with HER2-positive breast cancer who still have leftover cancer after surgery and standard pre-surgery treatment. It helps doctors choose the right therapy for you.
Beijing, Beijing MunicipalityAges Any age - NCT06587789Recruiting
Ribociclib plus hormone therapy for high-risk breast cancer
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
Hangzhou, ZhejiangAges 18–80 - NCT06698679Recruiting
Plasma markers and breast cancer risk & treatment
This study looks at substances in your blood (metabolites) to see if they are linked to breast cancer risk, how well treatment works, and long-term outcomes. It has three groups: women without breast cancer, newly diagnosed patients getting standard therapy, and those who have finished treatment.
Shenyang, LiaoningAges 18 years+ - NCT07616427RecruitingPhase 2
New drug plus hormone therapy for HER2-positive breast cancer
This study tests a new drug called fovinaciclib combined with hormone therapy and HER2-targeting drugs for early-stage breast cancer that has specific markers (HR-positive and HER2-positive). The goal is to shrink tumors before surgery and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07616453RecruitingPhase 2
New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT05891561RecruitingPhase 2
Short antibody treatment after surgery for early HER2+ breast cancer
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06711068Recruiting
Chemotherapy plus targeted therapy for HER2+ early breast cancer
This trial tests whether adding targeted therapy to chemotherapy after surgery can help prevent HER2-positive early breast cancer from coming back. It is for patients whose cancer has not spread to lymph nodes and who have certain tumor sizes and features.
Beijing, Beijing MunicipalityAges Any age - NCT04985266RecruitingPhase 2
Watch blood DNA for early breast cancer return, then add palbociclib
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
AngersAges 18 years+ - NCT07588425Recruiting
Monitoring heart health during breast cancer treatment
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
Ankara, AnkaraAges 18 years+ - NCT07593976RecruitingPhase 2
New PET scan to predict breast cancer treatment response
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
RouenAges 18 years+ - NCT07581834RecruitingPhase 2
Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Fuzhou, FujianAges 18 years+ - NCT07579286Recruiting
Skipping lymph node surgery in early breast cancer
This trial tests whether older women with early-stage, slow-growing breast cancer can safely skip removal of underarm lymph nodes during surgery. The goal is to reduce surgery-related side effects while maintaining safety.
Saint Petersburg, Russian FederationAges 60 years+ - NCT06722612Recruiting
Chemo plus targeted therapy for high-risk HER2+ early breast cancer
This trial tests whether combining chemotherapy with targeted therapy works better for women with high-risk, HER2 positive early breast cancer that hasn't spread to lymph nodes. If you've had surgery and your tumor fits certain high-risk features, you may be eligible to join.
Beijing, Beijing MunicipalityAges Any age - NCT07570524Recruiting
Predicting Treatment Response in Early Triple-Negative Breast Cancer
This study helps doctors predict which patients will respond best to immunochemotherapy (a combination of immune-boosting and chemotherapy drugs) for early-stage triple-negative breast cancer. By understanding your tumor better before treatment, doctors may be able to personalize your care plan.
RennesAges 18 years+ - NCT06728527Recruiting
Partial breast reconstruction with chest wall flap
This trial tests a specific type of partial breast reconstruction called a chest wall perforator flap. It's for women who previously had a lumpectomy and now want to improve the shape of their breast.
Cambridge, CambridgeshireAges 18 years+ - NCT07541079RecruitingPhase 3
Testing a New Breast Cancer Drug for Women Who Can't Tolerate Current Therapy
This study tests giredestrant, a new hormone-blocking medication, in postmenopausal women with early-stage ER+ breast cancer who have experienced intolerable side effects from their current aromatase inhibitor therapy. The trial will measure how well you tolerate this new drug and how it affects your quality of life.
Fountain Valley, CaliforniaAges 18 years+
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for early breast cancer?
- Yes. Clin2 currently lists 430 recruiting early breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a early breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a early breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.